The QualityStocks Daily Thursday, July 29th, 2021

Today's Top 3 Investment Newsletters

QualityStocks(XBIO) $5.3000 +65.11%

MarketClub Analysis(NTEC) $13.5500 +48.09% $3.9800 +38.19%

The QualityStocks Daily Stock List

RLX Technology (RLX)

Schaeffer's and MarketBeat reported earlier on RLX Technology (RLX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

RLX Technology Inc. (NYSE: RLX) (FRA: 3CM) is an e-vapor firm that is focused on the research, development, manufacture, distribution and sale of e-vapor products.

The firm has its headquarters in Beijing, the People’s Republic of China and was incorporated in 2018, on January 2nd by Yilong Wen, Long Jiang and Ying Wang. It serves consumers in China and operates as a RELX Inc. subsidiary.

The company’s mission is to make RELX a trusted brand for of age smokers via scientific advances, industry-leading technologies and state-of-the-art products, in partnership with committed and talented individuals and firms across the globe.

The enterprise is focused on holistically improving the experience of its adult smokers with their products, which is why it has implemented a multi-layered development framework that encompasses phase-transitions, interactions and accessories. It offers closed-system rechargeable e-vapor products with different value-added features. Its products are mainly sold in its offline retail outlets via its customer representatives, retailers and distributors. The enterprise serves RELX branded partner stores as well as other retail outlets via its distributors.

The firm recently reported its first quarter financial results for 2021, which show a nearly 50% increase in net revenue, in comparison with 2020’s fourth quarter results. Its CEO notes that the firm’s expansion of their distribution network coupled with a strong sequential growth demonstrated sustained user demand for its products. The firm is focused on further expanding its distribution network and enhancing supply chain and production capabilities. This will help extend consumer reach and boost the company’s growth.

RLX Technology (RLX), closed Thursday’s trading session at $4.47, up 2.0548%, on 10,224,269 volume. The average volume for the last 3 months is 7.236M and the stock's 52-week low/high is $4.05000019/$35.00.

ATI Physical Therapy (ATIP)

MarketBeat reported earlier on ATI Physical Therapy (ATIP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ATI Physical Therapy Inc. (NYSE: ATIP) is an outpatient orthopedic private practice that is engaged in the provision of outpatient physical therapy and high-quality rehabilitation services.

The firm has its headquarters in Bolingbrook, Illinois and was incorporated in 1996. It operates as part of the rehabilitation industry, under the healthcare sector and serves consumers in the United States.

The company distinguishes itself in the rehabilitation industry by taking a comprehensive approach, with emphasis on one-to-one, hands-on care. Its goal is to exceed consumer expectations, in every clinic, every day. The company operates in over 290 clinics in ten states. These are Tennessee, Georgia, Delaware, Pennsylvania, Maryland, Ohio, Michigan, Wisconsin, Indiana and Illinois. It has sustained remarkable growth, primarily due to new clinic openings and multi-clinic acquisitions, but also because of their unique approach to patient care, remarkable outcomes, innovative culture and the company’s expert team.

The enterprise provides complimentary injury screenings, home health, specialty therapies, women’s health, hand therapy, sports medicine, aquatic therapy, work conditioning/hardening, physical therapy, employer worksite solutions and workers’ compensation rehab services as well as research-based physical therapy and fitness centers, via its locations. It also provides online physical therapy through its CONNECT platform.

The firm recently reported its financial results for the 2nd quarter of 2021, with its CEO noting that they’d recorded an increase in the demand for its services. The firm’s CFO added that their strong balance sheet combined with other factors would help position the firm for long-term growth, which would encourage more investments into the company.

ATI Physical Therapy (ATIP), closed Thursday’s trading session at $3.63, off by 5.7143%, on 2,935,477 volume. The average volume for the last 3 months is 1.31M and the stock's 52-week low/high is $3.60999989/$13.0500001.

Allied Healthcare Products (AHPI)

MarketClub Analysis, BUYINS.NET, StockMarketWatch, TradersPro, QualityStocks, InvestorPlace, The Online Investor, MarketBeat, WiseAlerts, WealthMakers, Wall Street Mover, TopPennyStockMovers, Street Insider, Schaeffer's and PoliticsAndMyPortfolio reported earlier on Allied Healthcare Products (AHPI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Allied Healthcare Products Inc. (NASDAQ: AHPI) (FRA: AWI1) is focused on manufacturing, marketing and distributing respiratory products to be used in the healthcare industry, in alternate site settings and various hospitals globally.

The firm is based in St. Louis, Missouri and was founded in 1979. It serves emergency medical product dealers, home healthcare dealers, hospital construction contractors, hospital equipment dealers, hospitals and others.

The company serves consumers in the Far East, the Middle East, Europe, South and Central America, Mexico and Canada. It markets its products under the following brand names: Gomco, Lif-O-Gen, Oxequip, Chemetron, Schuco, Litholyme, Carbolime and Timeter, among others.

The enterprise provides home respiratory care products including portable suction equipment, pneumatic nebulizers, oxygen regulators and aluminum oxygen cylinders; respiratory care/anesthesia products comprising of equipment dryers, croup tents, humidifiers, calibration equipment and air compressors, as well as disposable respiratory products like ventilator circuits, cannulas and oxygen tubing products. It also offers medical gas equipment like central station pumps and compressors; regulation devices and suction equipment like pressure regulators and flowmeters; and disposable oxygen cylinders that offer oxygen for short periods. In addition to this, the enterprise provides emergency medical products that include resuscitation products like portable resuscitation systems, demand resuscitation valves, emergency transport ventilators; and trauma and patient handling products like trauma burn kits and pneumatic anti-shock garments.

The company recently started commercially shipping CBD (cannabidiol) from Colombia to Europe and Peru. This will help the company establish long term relationships with buyers in many markets across the globe, which will be useful for the firm when it expands its product offering. This move will also bring in more investors into the firm and boost its growth.

Allied Healthcare Products (AHPI), closed Thursday’s trading session at $5.94, up 5.7881%, on 4,399,736 volume. The average volume for the last 3 months is 5.051M and the stock's 52-week low/high is $3.45099997/$11.5399999.

Ambev (ABEV)

MarketClub Analysis, InvestorPlace, MarketBeat, Louis Navellier, Market Report, StocksEarning, Trades Of The Day, Daily Trade Alert, StockMarketWatch, Daily Profit, The Street, The Online Investor,, Market FN, Zacks, Investiv, Kiplinger Today, INO Market Report, StreetInsider, The Best Newsletters, Wyatt Investment Research, Investment U, ProfitableTrading, InvestorsObserver Team, Cabot Wealth, BUYINS.NET, Direction Alerts, AllPennyStocks, One Hot Stock, Promotion Stock Secrets, QualityStocks, Schaeffer's, Short Term Wealth, SmallCapVoice, StreetAuthority Daily, The Growth Stock Wire, Trade of the Week, Wealth Insider Alert and Navellier Growth reported earlier on Ambev (ABEV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ambev (NYSE: ABEV) (FRA: AMNA) (BMV: ABEVN) (BVMF: ABEV3) is engaged in the production, distribution and sale of food products, malt, carbonated soft-drinks, draft beer, beers and other non-alcoholic beverages in the Americas.

The firm has its headquarters in Sao Paulo, Brazil and was incorporated in 2005, on July 8th. It operates as part of the beverage manufacturing industry. The firm has more than 1000 companies in its corporate family and operates as a Interbrew International B.V. subsidiary.

The company operates through the Canada, Central America and Caribbean and Brazil geographical segments. The Canada segment is involved in the domestic sale of the company’s products in Canada and exports to the U.S. market. It represents the Labatt’s operations. The Caribbean and Brazil segment is focused on the NAB sales division and the beer sales division. On the other hand, the Central American segment comprises of its direct operations in Panama, Barbados, Guatemala, Cuba, Dominica, Antigua, Saint Vincent and the Dominican Republic. The company has exclusive distributor and bottler rights for Pepsi carbonated soft drink products in Brazil.

The enterprise provides beer mainly under the Kokanee, Alexander Keith’s, Labatt Blue, Busch, Michelob Ultra, Ouro Fino, Becker, Deputy, Huari, Pilsen, Banks and One brands. It also offers ready-to-drink teas, natural and powdered juices, coconut water, energy drinks, isotonic beverages and bottled water under the Palm Bay and Mike’s brands, Nutrl, Pepsi-Cola, Red Rock, Seven Up, Squirt, Canada Dry, Do Bem, Lipton Iced Tea, Natu and Gatorade brands. The enterprise provides its products via a direct distribution system and a network of 3rd party distributors.

As of January 2021, the firm had added 1000 electric cars to its fleet, with its objective being to operate on clean energy by 2023. As more countries and companies shift to the use of clean energy from fossil fuels, the emphasis on ESG standards grows. This move shows the company’s dedication to meeting net zero targets, which may bring in more investments into the firm.

Ambev (ABEV), closed Thursday’s trading session at $3.33, up 0.301205%, on 36,874,303 volume. The average volume for the last 3 months is 25.759M and the stock's 52-week low/high is $2.13000011/$3.95000004.


Wall Street Resources, Alliance Advisors, QualityStocks, TradersPro, The Wealth Report, StockMarketWatch, MarketBeat, InvestorPlace, StreetInsider,, The Bowser Report, Trades Of The Day, Investing Futures, Greenbackers, Daily Trade Alert, BUYINS.NET and PennyTrader Publisher reported earlier on SPAR Group (SGRP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

SPAR Group Inc. (NASDAQ: SGRP) (FRA: PMH) (JSE: SPP) is engaged in the provision of marketing and merchandising services globally to distributors, manufacturers and retailers.

The firm has its headquarters in Auburn Hills, Michigan and was incorporated in 1967 by William H. Bartels and Robert G. Brown. It serves consumers across the globe.

The company operates through the International and Domestic segments. The former segment provides audit, marketing, merchandising and in-store event staffing services in Turkey, South Africa, Mexico, Japan, India, China, Canada, Brazil and Australia while the latter segment offers services in the U.S. The company has an international presence through joint ventures and operations in the aforementioned countries, as well as in Romania and New Zealand. It serves home improvement, electronic, specialty, convenience, automotive, dollar, office supply and grocery stores, pharmacies, mass merchandisers and other retail outlets.

The enterprise provides syndicated services which include managing product inventory details, point of purchase and signage installation, implementing new item cut-ins that have been approved for distribution, rotation and replenishment of products on shelves, and implementing product and category resets. It also offers dedicated services like fixture installation services for various manufacturers and retailers. The enterprise also provides project services made up of particular in-store services initiated by manufacturers and retailers, like product recalls, promotional or special seasonal merchandising, new product launches and new store openings. In addition to this, it offers retail compliance and price audit, in-store event staffing and assembly services.

The firm recently appointed a new Chief Global Commercial Officer and Chief Strategy Growth Officer. These moves support the firm’s global expansion and further strengthen its executive team, which will have a positive effect on the firm’s growth and investments.

SPAR Group (SGRP), closed Thursday’s trading session at $1.95, off by 10.5505%, on 616,059 volume. The average volume for the last 3 months is 2.276M and the stock's 52-week low/high is $0.660000026/$3.85999989.

Xenetic Biosciences (XBIO)

StockMarketWatch, MarketBeat, TraderPower, MarketClub Analysis, QualityStocks, BUYINS.NET, TradersPro, TopPennyStockMovers, PCG Advisory, Wall Street Mover, TheMicrocapNews, The Online Investor, Real Pennies, PoliticsAndMyPortfolio and Daily Profit reported earlier on Xenetic Biosciences (XBIO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Xenetic Biosciences Inc. (NASDAQ: XBIO) (FRA: 3XB) is a biopharmaceutical firm that is focused on developing cell-based therapies that target the B-cell receptor on the surface of malignant tumor cells.

The firm has its headquarters in Framingham, Massachusetts and was incorporated in 2011 on August 9th. It operates as part of the pharmaceutical manufacturing industry, under the health care sector, in the biotech and pharma sub-industry. The firm has eleven companies in its corporate family and serves consumers in the U.S.

The company is party to collaboration agreements with SynBio LLC, PJSC Pharmsynthez, Serum Institute of India Ltd and Takeda Pharmaceutical Co. Ltd. In addition to this, it is also leveraging its proprietary drug delivery platform dubbed PolyXen by entering into partnerships with pharmaceutical and biotechnology companies. The company provides specialist delivery solutions using this platform, which improves the performance and efficacy of vaccines and drugs in various key medical areas, including oncology.

The enterprise’s product pipeline is made up of a personalized CART (chimeric antigen receptor T cell) platform technology dubbed XCART, which has been developed to target patient-specific tumor neoantigens. Additionally, it also develops XBIO-101, an oncology therapeutic investigational drug formulation which is indicated for the treatment of progestin resistant endometrial cancer.

The company recently obtained approval allowing it to begin its exploratory patient biopsy study which would evaluate its XCART candidate. The data generated by this study may position the firm to carry out Investigational Drug-enabling research in the U.S., which will encourage more investments into the firm.

Xenetic Biosciences (XBIO), closed Thursday’s trading session at $5.3, up 65.109%, on 63,202,752 volume. The average volume for the last 3 months is 7.47M and the stock's 52-week low/high is $0.75999999/$5.8499999.

Intec Pharma (NTEC)

MarketClub Analysis, Schaeffer's, MarketBeat, TraderPower, Top Pros' Top Picks, BUYINS.NET, StockMarketWatch, Zacks, Wealth Insider Alert, The Online Investor, StreetInsider, QualityStocks, InvestorPlace, and Barchart reported earlier on Intec Pharma (NTEC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Intec Pharma Ltd. (NASDAQ: NTEC) is a clinical stage biopharmaceutical firm that is engaged in the development of drugs that are based off of its proprietary gastric retention technology.

The firm has its headquarters in Jerusalem, Israel and was incorporated in 2000, on October 23rd by Zvika Joseph. Prior to its name change in March 2004, the firm was known as Intec Pharmaceuticals Ltd. It operates as part of the scientific research and development services industry under the healthcare sector in the biotech and pharma sub-industry. The firm serves consumers in the United States.

The enterprise is party to a CBD research collaboration agreement and a research collaboration agreement with GW Research Limited and Merck Sharp & Dohme respectively. Its efforts are directed to its clinical trials as well as research and development. It develops drug formulations through the use of its Accordion Pill platform technology, which has been designed to enhance the safety and effectiveness of drugs that are currently being developed by using an efficient and specific gastric retention and release mechanism.

The enterprise’s product pipeline is made up of AP-CBD, AP-THC and AP-THC/CBD, which are indicated for various pain indications; Accordion Pill Zaleplon, which is undergoing a phase three clinical trial to test its effectiveness as a treatment for insomnia as well as small bowel and gastroduodenal NSAID induced ulcers. In addition to this, the company develops the Accordion Pill Carbidopa/Levodopa, which is indicated for treating Parkinson’s disease symptoms.

The firm’s Merck Sharp & Dohme cannabinoid research collaboration agreement may soon bring in hefty returns, given the popularity of the marijuana market and its legalization across the country, as well as bringing in more investors into the firm.

Intec Pharma (NTEC), closed Thursday’s trading session at $13.55, up 48.0874%, on 34,234,066 volume. The average volume for the last 3 months is 420,280 and the stock's 52-week low/high is $8.80000019/$36.880001.

FEC Resources, Inc. (FECOF)

QualityStocks, Pennybuster and MarketBeat reported earlier on FEC Resources, Inc. (FECOF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

FEC Resources, Inc. engages in the acquisition, exploration, and, when warranted, development of natural resource and mineral properties. The Company is a subsidiary of PXP Energy Corporation (Philex) who holds 54.99 percent of the undiluted issued and outstanding capital of FEC. The chief investment of FEC Resources is a 6.80 percent stake in the United Kingdom (UK) company Forum Energy Limited (FEL). The Company previously went by the name Forum Energy Corporation. It changed its name to FEC Resources, Inc. in May of 2005. Incorporated in 1982, FEC Resources is based in Vancouver, British, Columbia. FEC lists on the OTC Markets.

Forum Energy Limited's primary asset is a 70 percent interest in the GSEC101 offshore licence situated to the northwest of the Philippine island of Palawan. This area is roughly 10,360 Km2. It contains the Sampaguita gas discovery, which has expected gas in place of 3.4TCF and potential upside to 20 TCF (Trillion Cubic Feet). Furthermore, FEC Resources has an investment in a gold exploration project in the Philippines.

In addition, the Company owns 8.46 percent, 12.40 percent, and 19.46 percent interests in the SC 14A Nido, SC 14B Matinloc, and SC 14B-1 North Matinloc located in the offshore northwest Palawan. FEC also owns 9.10 percent in SC14C-2; 5.56 percent and 8.18 percent in SC 6A Octon and SC 6B Bonita positioned in the offshore northwest Palawan.

Moreover, FEC Resources owns a 100 percent interest in the SC 40 North Cebu, covering an area of 340,000 hectares in the northern part of Cebu Island and adjacent offshore areas located in the Visayan Basin in the central part of the Philippine Archipelago, and as well as 2.27 percent interest in SC14C-1 Galoc.

FEC Resources previously regrettably announced that Mr. Lyle Brown will be retiring from the Board of the Company for health reasons effective October 31, 2020. At present, Mr. Brown acts as an Independent Non-Executive Director and Chairman of FEC Resources’ Audit Committee.

Mr. Paul Wallace, President of FEC Resources, stated, "We were fortunate indeed to have Lyle join us in 2013. He offered an independent mindset and came with a reputation of being a professional accountant of high integrity. He has provided the Board with his considered and informed views on the various accounting and valuation issues we have faced in recent years. We thank him for his service and wish him the very best for the future."

FEC Resources, Inc. (FECOF), closed Thursday’s trading session at $0.03, up 42.8571%, on 4,717,443 volume. The average volume for the last 3 months is 1.034M and the stock's 52-week low/high is $0.0012/$0.048999998.

Eco Depot, Inc. (ECDP)

StockRockandRoll,, StockLockandLoad,, PennyStocks24, Research Driven Investor, Michael Stone, Growing Stocks Reports, Xtreme Stock Picks, SmallCapInvestorDaily, PennyStock MarketBulls, Pumps and Dumps, RagingStock Bull, JackpotStock Picks, Super Hero Stocks, PennyStock PayCheck, Wallstreet Profiler, The Observer, PennyDoctor, Blaque Capital Stocks, PennyStock Tweets, Penny Stock Mobsters, Daily Stock Motion, Penny Pick Insider, Stockgoodies, Email Stock Picks, Penny Stocks VIP, InvestorTrendz, Penny Stocks Finder, MassiveStockProfits, Penny Stocks On Steroids, Beacon Equity Research, PennyStockScholar, POSstocks, MajorPennyStocks, PremiereStockAlerts, Penny Picks, Jet-Life Penny Stocks, OTCtipReporter, StockProfessors, WINNINGOTC, Wall Street Beauties, Darth Trader, The Stock Psycho, SuperStockTips, InvestorSoup, Equity Observer, Research Driven Alerts, StockMarketIntel, SizzlingStockPicks, ResearchOTC, Penny Stock Craze, smartOTC, Stock Preacher, BestDamnPennyStocks, Damn Good Penny Picks, OtcShortReport, Joe Penny Stocks, DSR News, FOX Penny Stocks, Epic Stock Picks, Liquid Pennies, EpicVIP Group, HotStockProfits, Liquid Tycoon, Greenbackers, HEROSTOCKS, LuckyStockPicks,, USA Market News,, StockMister, StreetAuthority Financial, Super Nova Stock Picks, SuperHotPennyStocks, Stock Brain, Top Stock Picks, SmallCap Fortunes, Value Penny Stocks, VIP STOCK ALERTS and Wallstreetbuzz reported earlier on Eco Depot, Inc. (ECDP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Eco Depot, Inc. acquires, manages, as well as develops eco-friendly real estate assets and consumer brand products. The Company’s focus is to provide investments, funding, and support for acquisitions, start-ups, entrepreneurs, and green companies committed to protecting the environment. A Nevada company, and founded in 2004, Eco Depot lists on the OTC Markets. The Company is headquartered in Las Vegas, Nevada.

Currently, Eco Depot is focused on commercializing Bronya Climate Shield. This is a versatile thermal insulation paint capable of increasing energy efficiency and decreasing carbon emissions.

Bronya Climate Shield™ is a multi-purpose liquid insulation. It can be applied on any surface, indoors and outdoors, at temperatures of -60 °C up to +200 °C. Bronya Climate Shield is a cost-effective Do-It-Yourself (DIY) product with thermal conductivity of 0,001 W/m Celsius. It is proven to lessen energy costs by up to 40 percent and labor costs by 70 percent. In addition, the product provides insulation lasting from 10 to 30 years, depending on the application.

Eco Depot previously announced it completed labs to meet the ISO Fire Retardant Standards for Nordic Structures prefabricated I-Joist building products manufacturing. Lab results from studies conducted by FPInnovations, sponsored by Nordic Structures, as a potential economic advantage to fire proofing OSB manufactured I-Joists, have marked Bronya Climate Shield Thermal Liquid Insulation as "Promising" and functionally meeting ISO minimum Fire Retardant Standards. The lab results will be made available in a supplementary filing. They are also available by request at Eco Depot corporate.

Eco Depot, Inc. (ECDP), closed Thursday’s trading session at $1.45, up 36.7925%, on 282,338 volume. The average volume for the last 3 months is 116,879 and the stock's 52-week low/high is $0.012099999/$5.57999992.

DATATRAK International, Inc. (DTRK)

QualityStocks, MarketBeat and StreetInsider reported earlier on DATATRAK International, Inc. (DTRK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

DATATRAK International, Inc. is a global Software-as-a-Service (SaaS) provider and innovation leader of cloud-based technologies for the life sciences industry. The Company delivers unified eClinical solutions and related services for the clinical trials industry. DATATRAK delivers a complete portfolio of software products designed to hasten the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. Founded in 1991, DATATRAK International is based in Cleveland, Ohio, and College Station, Texas. The Company lists on the OTC Markets.

DATATRAK International built its multi-component, complete solution on a single, unified platform. The DATATRAK software solution, deployed internationally through an ASP or Enterprise Transfer offering, supports Pre-clinical, Phase I – Phase IV drug, device and diagnostic studies in many languages. The DATATRAK Enterprise Cloud includes Business Intelligence, CTMS, Trial Design, Electronic Data Capture (EDC), Medical Coding, Risk-Based Monitoring, ECG Data Capture, Image Data Capture, Endpoint Adjudication, Randomization, Clinical Supply Inventory, eConsent, ePRO, and eCOA.

The Company’s vision moving forward is to continue to build and own a multilingual and multi-tenant enterprise platform with unified access to clinical applications, database, as well as workflows. Additionally, its emphasis is to ensure scalable and operational efficiency. This is while eliminating the need for back-end integration that is the cause of common friction points.

DATATRAK International’s commitment is to enabling workgroup teams with role-based access to version-controlled file management, calendar events, tasks and contacts, all built within their eClinical applications. This includes EDC, CTMS, reporting, data analytics, and business intelligence.

DATATRAK International, Inc. (DTRK), closed Thursday’s trading session at $14.8, up 33.3333%, on 6,979 volume. The average volume for the last 3 months is 1,238 and the stock's 52-week low/high is $3.25/$15.9300003.

Snap Inc. (SNAP)

InvestorPlace, The Street, Schaeffer's, MarketClub Analysis, MarketBeat, Trades Of The Day, StreetInsider, StocksEarning, Daily Trade Alert, Zacks, Kiplinger Today, Market Intelligence Center Alert, The Online Investor, Wealth Insider Alert, Investopedia, CNBC Breaking News, The Street Report, Barchart, INO Market Report,, StockMarketWatch, StreetAuthority Daily, Trading Concepts, Louis Navellier, Profit Confidential, Market Intelligence Center, Daily Profit, Top Pros' Top Picks, TopStockAnalysts, Money Morning, Investors Alley, GorillaTrades, AllPennyStocks, 24/7 Trader, InvestmentHouse, Uncommon Wisdom, QualityStocks, The Wealth Report, Total Wealth, MarketTamer, Trading Tips, Investment U, Investing Daily, Investiv, MarketWatch, Max Wealth, Energy & Resources Digest, Economy & Markets, Early Bird, Dynamic Wealth Report, StockGuru, Wall Street Window, SmallCap Network, FreeRealTime, Epic Stock Picks, Direction Alerts, Daily Wealth, Cabot Wealth, BUYINS.NET, Schaeffer’s, wyatt research newsletter, Wealth Week, Wealth Daily, Wall Street Profit Search, Wall Street Daily, TipRanks, Technology Profits Daily, StrategicTechInvestor, Money and Markets, StockEarnings, InvestorsObserver Team, Promotion Stock Secrets, ProfitableTrading, Power Profit Trades, PennyStockLocks, Penny Stock 101, Penny Picks, MarketClub, Jon Markman's Pivotal Point, Jon Markman’s Pivotal Point and StockRockandRoll reported earlier on Snap Inc. (SNAP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Snap Inc. (NYSE: SNAP), a company that believes reinventing the camera represents the greatest opportunity to improve the way people live and communicate, was featured in this week’s Simply Wall St Journal. The piece covers SNAP’s performance and analysis on timing for entering the stock. “Are you a shareholder? It seems like the market has well and truly priced in SNAP's positive outlook, with shares trading above our estimates of fair value. At this current price, shareholders may be asking a different question: should I sell? If you believe SNAP should trade below its current price, selling high and buying it back up again when its price falls towards its real value can be profitable.

But before you make this decision, take a look at whether its fundamentals have changed,” the publication reads. “If you decide to hold the stock, you may want to monitor Snap's growth rates each quarter, daily active users and revenue per user to make sure the company is still on track. Are you a potential investor? If you've been keeping an eye on SNAP for a while, now may not be the best time to enter into the stock. The price has surpassed its estimated fair value, which means there's potentially not much upside from mispricing. However, the optimistic prospect is encouraging for SNAP, which means it's worth diving deeper into other factors in order to take advantage of the next price drop.”

For more details, visit

Snap is a camera company. It believes that reinventing the camera represents the greatest opportunity to improve the way people live and communicate. Snap contributes to human progress by empowering people to express themselves, live in the moment, learn about the world, and have fun together. For more information, visit

Snap Inc. (SNAP), closed Thursday’s trading session at $74.92, off by 1.6282%, on 15,807,836 volume. The average volume for the last 3 months is 18.992M and the stock's 52-week low/high is $20.6100006/$79.1800003.

Mastech Digital, Inc. (MHH)

Wall Street Resources, StockMarketWatch, InvestorPlace, Zacks, Barchart, BestOtc, CRWEFinance, CRWEPicks, CRWEWallStreet, DrStockPick, alert, PennyOmega, PennyToBuck, QualityStocks, StockHotTips, TopPennyStockMovers and MarketBeat reported earlier on Mastech Digital, Inc. (MHH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Mastech Digital (NYSE American: MHH) was featured in a company-sponsored research earnings release note published by Sidoti & Company, LLC. The report reads, “2Q:21 Results Show Healthy Year-To-Year Gains, Signs Of A Rapidly Recovering Data & Analytics Business; EPS Upside Due To Lower SG&A; Valuation Attractive To Us, Maintain $31 Price Target.”

To access the full report, visit

Mastech Digital is a leading provider of Digital Transformation IT Services. The company offers Data Management and Analytics Solutions, Digital Learning, and IT Staffing Services with a Digital First approach. A minority-owned enterprise, Mastech Digital is headquartered in Pittsburgh, PA with offices across the U.S., Canada, EMEA, India and ASEAN. Please visit

Mastech Digital, Inc. (MHH), closed Thursday’s trading session at $17.2, off by 7.1274%, on 41,636 volume. The average volume for the last 3 months is 47,595 and the stock's 52-week low/high is $14.00/$25.2600002.

The QualityStocks Company Corner

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX).

  • Lexaria Bioscience is a drug delivery technology developer advancing its IP for transforming existing consumer products and medications that may improve their availability and bioavailability
  • The analysis of Lexaria’s DehydraTECH(TM) shows it did not create unwanted new molecular entities during the transformation process, did not inhibit the drugs’ expected antiviral functions and did increase absorption
  • The DehydraTECH testing has been in conjunction with drugs used to treat SARS-CoV-2/COVID-19, HIV/AIDS and hepatitis, although the company envisions its technology becoming responsive to a much wider array of viral illnesses
  • The company envisions building on its recent successes with larger studies of the DehydraTECH process in animals infected with viruses such as SARS-CoV-2/COVID-19 or HIV/AIDS and hopes to eventually form partnerships with established pharmaceutical giants

Oral drug delivery platform innovator Lexaria Bioscience (NASDAQ: LEXX)provided investors an update July 22 on the success of its efforts to advance its proprietary technology toward scalable commercial use for improving the treatment of select viral illnesses. 

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released results from its recent human clinical study focused on evaluating DehydraTECh(TM)-processed cannabidiol ("CBD") for potential application against hypertension. The study, HYPER-H21-1, indicated a rapid, sustained drop in blood pressure with DehydraTECH-CBD as well as excellent tolerability. The partial results will be followed by more complete results after additional BP subset analyses and other data analyses are completed. To view the full press release, visit

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 19 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Thursday’s trading session at $6.7, up 4.3614%, on 380,031 volume. The average volume for the last 3 months is 1.967M and the stock's 52-week low/high is $3.97510004/$12.50.

Recent News

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC)

The QualityStocks Daily Newsletter would like to spotlight BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC).

As cannabis is legalized for recreational use in more states across the country, the popularity of cannabis products is increasing, especially cannabis drinks. Companies such as BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) have advanced the science of making cannabis beverages to such an extent that the segment is light years ahead of where it started.

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) is a diversified health & wellness beverage and natural products company focused on developing and manufacturing a range of plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients. The BevCanna team boasts decades of experience creating, manufacturing and distributing iconic brands that resonate with consumers on a global scale.

BevCanna’s distribution network features more than 3,000 points of retail distribution through the company’s market-leading TRACE brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network and its partnership with #1 U.S. cannabis beverage company Keef Brands.

Based in British Columbia, Canada, BevCanna was founded in 2017.

End-to-End Turnkey Beverage Manufacturing Solutions

BevCanna is a manufacturer of traditional and cannabis-infused beverage brands serving a growing roster of white-label clients, in addition to operating a portfolio of in-house and partner brands. The company offers a full-service white label beverage manufacturing solution.

  • Processing – At its state-of-the-art beverage manufacturing facility, BevCanna partners with industry leaders specializing in crude extraction, refinement, purification and solubility conversion to provide high-quality water-immiscible emulsions that maximize bioavailability, clarity and taste.
  • Spring Water – BevCanna directly owns a pristine naturally alkaline spring water aquifer in British Columbia.
  • Product Development – BevCanna leverages its expertise to develop captivating flavors based on category and consumer insights in order to enhance product positioning.
  • Packaging – A variety of packaging options are offered by BevCanna, including beverage and nutraceutical formats such as PET, aluminum and glass, available in a variety of standard and custom sizes and shapes.
  • Beverage Manufacturing: Traditional & Cannabis Facilities – The company’s 40,000-square-foot beverage manufacturing facility is HACCP (Hazard Analysis Critical Control Point) Certified. The facility’s capabilities include blow molding, dosing, carbonation options, filling and capping, pressure sensitive and shrink-sleeve label applications, flash pasteurization, QA testing and packing/palletizing for shipment.

Pure Therapy, TRACE and Partner Brands

BevCanna’s in-house brands include Pure Therapy and TRACE.

Pure Therapy is a direct-to-consumer e-commerce brand that markets a range of natural health products, including nutraceuticals and hemp-based cannabidiol (CBD) products, throughout North America and Western Europe.

Pure Therapy has secured orders from over 23,000 customers since its inception in 2017. BevCanna expects strong growth through Pure Therapy over the next 12 months driven by new product integration, accelerated growth of existing products and its marketing team’s e-commerce expertise.

TRACE products feature the Naturo Group’s proprietary plant-based fulvic and humic mineral formula, sourced from deep within the Rocky Mountains of interior British Columbia. These unique and ancient minerals provide wellness properties that include iron, magnesium, calcium, potassium and many other minerals no longer found in our food chain at adequate levels.

Research suggests that the proprietary fulvic and humic organic compounds found in TRACE products could offer a number of key benefits, including promoting gut health, immune function, cognitive performance and whole-body wellness.

TRACE products include Natural Alkaline Spring Water, Plant-Based Mineralized Spring Water, Natural Flavor Sparkling Spring Water, Plant-Based Mineral Concentrate with Vitamin D and Plant-Based Mineralized Immune Support Shots.

In addition to its in-house brands, BevCanna provides white-label services to a number of partners in its space. BevCanna’s current portfolio of brand partnerships includes #1 U.S. cannabis beverage brand Keef (cannabis-infused classic soda) and BLOOM (live resin & high-end extracts). BevCanna also has multiple white label agreements to co-manufacture branded beverages.

Market Outlook for Cannabis-Infused Beverages

In 2018, the cannabis-infused beverage market was valued at $901.8 million. The market is expected to grow during the forecast period of 2019 to 2025 at a CAGR of 17.8%, resulting in a market value in excess of $2.84 billion by 2025, according to Grand View Research (

The projected growth is largely attributed to the legalization of recreational and medical marijuana in multiple jurisdictions. Cannabis-infused beverages are uniquely positioned to provide an alternative to a large portion of the edibles market, including items such as chocolates, cookies, gummies and other types of confectionery pieces.

Management Team

Marcello Leone is the CEO and Founder of BevCanna. He is also the founder of Naturo Group and the TRACE brand.

John Campbell is the CFO and CSO of BevCanna. He has over 30 years of experience in the investment industry, including time with TriView Capital Ltd.

Keith Dolo is the company’s Executive Management Advisor, having previously served as CEO and Executive Chairman of Sproutly Inc. Previously, he served for over 13 years with Robert Half (NYSE: RHI), an S&P 500 company, specifically in the role of Vice President for the last eight years.

Melise Panetta is the company’s President. She is an accomplished senior marketing and sales executive with extensive experience leading organizations such as SC Johnson, General Mills (NYSE: GIS) and PepsiCo (NASDAQ: PEP). Ms. Panetta has nearly 15 years of deep marketing and sales expertise.

Raffael Kapusty is the company’s Vice President of Sales & Insights. She is an accomplished CPG industry leader with more than 25 years of experience in both the Canadian and U.S. retail spaces. With a solid foundation at ACNielsen Canada (NYSE: NLSN), Ms. Kapusty has developed a deep understanding of the CPG space, working with over 100 leading Canadian & global CPG manufacturers. She has also held senior category and key account management roles at Kroger (NYSE: KR), SC Johnson and Unilever Canada (NYSE: UL).

Bill Niarchos is the company’s Vice President of Sales & Sales Operations. He has over 20 years of experience in the CPG goods industry/retail environment. In his most recent role as Director of Sales with Bayer Consumer Health, Mr. Niarchos managed the strategic direction and growth of Loblaw & SDM. Prior to his position with Bayer (ETR: BAYN), Mr. Niarchos held a number of progressive roles at Colgate Palmolive (NYSE: CL) for more than 14 years.

Japheth Noah is the company’s Head of Quality Assurance. He is an Oxford and MIT educated quality and regulatory manager with over 15 years of experience in the beverage, pharmaceutical, natural health and medical industries.

Keith Stride is the company’s Creative Director. He has 25 years of experience in marketing and advertising, including time in a CMO role with Hemptown USA. Mr. Stride is internationally recognized for building high-profile brands, including Rogers (NYSE: RCI), TD Bank (NYSE: TD), Best Buy (NYSE: BBY), Whistler-Blackcomb and RBC (NYSE: RY).

BevCanna Enterprises Inc. (OTCQB: BVNNF), closed Thursday’s trading session at $0.4249, up 1.4081%, on 237,581 volume. The average volume for the last 3 months is 165,077 and the stock's 52-week low/high is $0.125/$1.20000004.

Recent News

Splash Beverage Group Inc. (OTCQB: SBEV)

The QualityStocks Daily Newsletter would like to spotlight Splash Beverage Group Inc. (OTCQB: SBEV).

Splash Beverage (NYSE American: SBEV) chairman and CEO Robert Nistico was the featured guest in a recent interview. is a corporate investor relations firm recognized for its ability to help emerging growth companies, small cap and micro-cap stocks build a following among retail and institutional investors. During the interview with host Stuart Smith, Nistico talked about Splash Beverage’s business strategy as well as industry trends and metrics. Nistico noted that corporate success is often proportionate with qualified leadership, and Splash Beverage leadership includes a highly experienced management team, a strong board of directors, and a roster of professionals who have built invaluable industry relationships, as well as specialties in nutrition, marketing and other relevant spaces. To view the full interview, visit To view the full press release, visit

Splash Beverage Group Inc. (OTCQB: SBEV) is a portfolio company of successful beverage brands with the objective of driving value through superior production, supply chain efficiency and global distribution capabilities.

Specializing in manufacturing, distributing, sales & marketing of various beverages across multiple channels, the company operates in both the alcoholic and non-alcoholic beverage segments, allowing it to leverage efficiencies and dilute risk. The company’s business strategy is to quickly develop and/or accelerate pre-existing brands to exit for cash events. Led by a highly successful management team, the company only works with brands it perceives to have highly visible preexisting brand awareness or pure category innovation, thus breaking through the clutter. Splash seeks out brands offering products that:

  • Deliver natural quality, health benefits, freshness and refreshment within their beverages;
  • Are on trend with consumers;
  • Have a high level of brand awareness;
  • Maintain highest performance standards and focus on execution;
  • Help distributors and retail partners achieve and exceed all goals; and
  • Offer unapologetic support for members of the U.S. armed forces, first responders and health care professionals.

Splash was founded in 2013 and is located in Fort Lauderdale, Florida.

Splash Portfolio

The current Splash portfolio includes four unique beverage brands. Each of these brands offers one or more of the qualities that the company specifically seeks in an acquisition.

  • TapouT Performance is a natural isotonic hydration & recovery sport drink featuring a 3-in-1 advanced formula. TapouT Performance restores what the body loses through physical exertion, delivering hydration and cellular recovery. Perfectly balanced with key vitamins & minerals and all five necessary electrolytes, TapouT increases nutrient absorption, allowing the body to recover quickly and more efficiently. TapouT is the official training partner of the WWE (NYSE: WWE).
  • Salt Naturally Flavored Tequila is a 100% blanco agave 80 proof tequila that offers a clean and delicate taste. Salt is grown, distilled and bottled in the Jalisco region of Mexico. Every bottle of Salt Tequila is the result of hard work, determination and numerous blends. The brand offers a line of tequila flavors for enhanced refreshment, including berry, citrus and salted chocolate.
  • Copa Di Vino is the leading producer of premium “wine by the glass” in the U.S. Produced in the Columbia Valley, Copa di Vino is readily available on the go without the requirement of a bottle, corkscrew or glass. Open, drink and enjoy.
  • Pulpoloco Sangria is a premium crafted sangria imported from Spain. Its flavor is light-bodied, fruity and refreshing, offering the best blend of Spanish ingredients. The product is filled and packed in a unique eco-friendly biodegradable catocan, allowing Pulpoloco to extend the shelf life of the sangria without the use of preservatives.

Market Outlook

The global beverage industry was valued at $1.5 trillion in 2018 and is projected to grow at a CAGR of 3.1%, reaching a market size of $1.9 trillion by 2024 ( The push for non-alcoholic beverages that are healthier and contain zero sugar is expected to be a driving force in the forecast period and beyond.

With a seasoned management team and sufficient capital to fuel sustained growth, Splash is uniquely positioned to capitalize on this market growth. The company is currently preparing a secondary offering and has engaged Kingswood Capital Markets as lead underwriter in order to uplist to the Nasdaq or NYSE in the near future.

Management Team

Robert Nistico is the Chairman and CEO of Splash Beverage Group. He has 28 years of experience in the beverage industry and was the fifth employee and SVP/General Manager of Red Bull North America. In this role, he led the start-up from zero sales to $1.65 billion in annual sales. Mr. Nistico was a founder and President of Marley Beverages and was responsible for framing the company’s long-term vision. Mr. Nistico held executive positions at DIAGEO, Republic National Distributing Company and the Gallo Wine Company resulting in decades of successful experience in the ‘Three Tier Beverage System’. In the spirit of his true entrepreneurial nature, he is a motivated, results-driven, creative and passionate leader.

William Meissner is the company’s President and CMO. He boasts over 20 years of success in growing consumer brand companies with large and medium-sized entrepreneurial organizations, both locally and internationally. His résumé includes multiple CEO roles, leading efforts to revamp both healthy and distressed companies. Before joining Splash, Mr. Meissner was the President and CEO of Sweet Leaf and Tradewinds Tea. He has held multiple positions with leading companies in the beverage sector, including Sparkling Ice, Jones Soda, SoBe Beverages, Fuze & NOS (Coca-Cola) and many others.

Sanjeev Javia is the Vice President of Product Development for Splash. He is the founder and President of Javia Wellness Group, a firm focusing on the innovation, research, formulation and design of healthy exercise and wellness initiatives. Mr. Javia is a sports nutrition expert, allowing him the advantage of developing innovative functional beverages that include health benefits for consumers. Since 2000, he has advised and written nutritional plans for hundreds of the world’s most famous athletes, including Tom Brady, Kurt Warner, Curt Schilling and more.

Dean Huge is the company’s Chief Financial Officer. He brings 35 years of public and private sector accounting and finance experience to the Splash Beverage team. Mr. Huge has led four public offerings as CFO and guided the growth efforts of numerous companies, including Catalyst Energy Corp., which was named Inc. Magazine’s ‘Fastest Growing Company’ within 36 months of his joining. His expertise spans financial services, manufacturing, distribution and SAAS-type programs.

Aida Aragon is the company’s Senior Vice President of National Accounts. She is a sales, marketing and brand management executive with years of experience working in the sports supplement and beverage industry. In her previous positions, Ms. Aragon was vital in leading successful store rollouts for brands including Muscle Milk. Her passion for brand development comes as second nature, but her true passion has always been focused on increasing sales for brands in the sports nutrition industry.

Splash Beverage Group Inc. (SBEV), closed Thursday’s trading session at $2.92, up 4.6595%, on 121,307 volume. The average volume for the last 3 months is 390,926 and the stock's 52-week low/high is $1.64999997/$15.3000001.

Recent News

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF)

The QualityStocks Daily Newsletter would like to spotlight Avricore Health Inc. (OTCQB: AVCRF).

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) was featured in a recent episode of the “PBA à Noon” podcast hosted by Paul Benwell & Associates. Avricore Health’s CEO Hector Bremner joined the program to discuss the company’s point-of-care testing platform, HealthTab(TM), which it recently launched in the first of 11 Shoppers Drug Mart pilot locations. The program’s initial focus is to screen patients at risk for diabetes and cardiovascular disease, as well as to support already diagnosed patients in better managing their conditions for a higher quality of life. “HealthTab is our flagship product at Avricore Health,” Bremner said, discussing the company’s keystone mission to address a very prominent issue in the health tech space and the primary health care delivery space. “That is bringing in technologies and modernizing the pharmacy practice. . . . Our vision is to create the world’s largest rapid-testing network in community pharmacies and make actual health insights more accessible to everyone.” To watch the podcast, visit

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering, HealthTab™ (a wholly owned subsidiary), the company aims to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.


HealthTab is a turnkey point-of-care testing solution that effectively turns pharmacies into diagnostic hubs (sometimes known as ‘Community Diagnostic Centers’, or CDCs) and connects them on a single, cloud-based platform.

The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery and empowers patients to take more control of their health. It also reduces costs and waiting times while providing many potential revenue streams, including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets and third-party app integration through API.

Agreement with Shoppers Drug Mart

In June 2021, Avricore signed a Master Agreement with select Shoppers Drug Mart pharmacies to pilot the HealthTab platform. This agreement gives patients access to point-of-care blood screening and health-data management for potential risks relating to diabetes and cardiovascular conditions using HealthTab-integrated Afinion 2™ analyzers provided by Abbott Rapid Diagnostics.

Avricore is the first pharmacy solutions provider to partner with Abbott (NYSE: ABT), the global health care company and diagnostics leader in Canada. In May 2021, the company signed a supplier distribution agreement to expand the distribution of Abbott’s Afinion 2 and associated tests for diabetes and heart disease screening in community pharmacies in Canada. This agreement includes valuable HbA1c testing, a critical marker for the screening and management of diabetes.

Near Term Goals

Near term goals for Avricore include expansion into more pharmacies across Canada, followed soon after by entering the U.S. and UK markets. The company has made significant strides in testing and developing its technology and is moving into the commercialization stage.

Strategic partnerships like those with Abbott and select Shoppers Drug Mart pharmacies advance Avricore closer to becoming an incredibly dominant player in the community diagnostics space. The company aims to make actionable health information more accessible for everyone by creating the world’s largest rapid testing network in pharmacies.

Market Outlook

In 2020, the global point-of-care testing (POCT) market was valued at $34.49 billion and expected to expand at a compound annual growth rate (CAGR) of 9.4 percent to reach a projected $81.37 billion by 2028. This upsurge is expected to be driven largely by increased demand for screening and management tools for chronic diseases, as well as rapidly assessing infectious diseases such as COVID-19.

The accessibility of POCT has been an increasing priority of the world’s leading health organizations and experts. Pharmacies are ideal ‘hubs’ within the community to offer patients better access to the numbers they need to know for preventing or treating conditions such as diabetes and heart disease or the timely diagnosis of infection.

Management Team

Avricore’s leadership team brings a diverse portfolio of expertise across the health care and biotech industries, as well as technology, finance and communications. Together, they share a common vision of moving pharmacy forward and have positioned the company for significant future growth and expansion.

Hector Bremner is the CEO of Avricore. He has over 15 years of senior and executive experience across various industries, including international trade, natural gas, marketing and communications. He owned and operated TOUCH Marketing, a boutique marketing and communications firm based in Vancouver, from 2007 to 2013. Mr. Bremner has also served as the executive assistant to the Deputy Premier and Minister of Natural Gas Development, Responsible for Housing, as well as the Minister of International Trade and Minister of Small Business. In 2015, he joined Vancouver’s Pace Group Communications as VP of Public Affairs.

David Hall is the Chairman and a Director of Avricore. His leadership spans five different companies. He is currently the Chairman of RepliCel Life Sciences and a member of the boards of TrichoScience Innovations, AdvantageBC and Providence Health Care Research Institute. Mr. Hall also served as Chairman of Perceptronix Medical Inc.; Chief Financial Officer, Secretary & Treasurer of Angiotech Pharmaceuticals Inc.; President & Director at Newcastle Resources Ltd.; and Chairman for LifeSciences British Columbia.

Kiki Smith is Avricore’s CFO. She has over 20 years of experience assisting private and public companies in the roles of accountant, corporate controller and CFO in mining, oil & gas, real estate, high technology, food production and investment fund management. She currently provides consulting services in M&A, financial reporting and regulatory compliance to several public and private companies across several investment sectors. Ms. Smith is a member of the Chartered Professional Accountants of British Columbia and has a bachelor’s degree in economics from the University of British Columbia.

Rodger Seccombe is the Head of Avricore’s HealthTab division and the co-founder and former CEO of HealthTab Inc. Mr. Seccombe has over 20 years of experience launching and running companies in software, health care technology and clean energy. He is a recognized industry expert in direct-to-consumer and point-of-care testing technology. In 2006, he joined the start-up team at Canadian Bioenergy Corporation and helped pioneer the development of the renewable fuel industry in Canada. Before HealthTab, he designed and developed cloud-based informatics systems currently in use by some of the world’s leading medical laboratories and instrument manufacturers.

Avricore Health Inc. (OTCQB: AVCRF), closed Thursday’s trading session at $0.1392, even for the day, on  volume. The average volume for the last 3 months is 8,599 and the stock's 52-week low/high is $0.013269999/$0.485619992.

Recent News

Sustainable Green Team Ltd. (SGTM)

The QualityStocks Daily Newsletter would like to spotlight Sustainable Green Team Ltd. (SGTM).

Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, is maximizing profit through its synergistic business model that incorporates its subsidiaries. The model enables it to receive mulch feedstock of high quality at a much lower net cost for maximum profit. “SGTM broke records in 2020 with year-over-year increases of 764% in revenue and 4,817% in gross profit, and the trend continued for Q1-2021 with quarter-over-quarter increases of 16.7% in revenue and 8.6% in gross profit,” a recent article reads. “The company’s business model — unique to the industry — allows it to profit in two ways: first by offering paid services that enable it to acquire its feedstock and second by processing and selling the transformed product to large-scale commercial retailers such as The Kroger Co., Circle K, Menards Inc. & Old Castle Lawn & Garden. ‘This business combination has created an industry powerhouse, and with our combined strengths put us in an ideal position to increase our sales and resulting margins as our combined operations benefit from the resulting vertical integration and economies of scale,’ said Mulch Manufacturing CEO Ralph Spencer.” To view the full article, visit

Sustainable Green Team Ltd. (OTC: SGTM), through its subsidiaries, including National Storm Recovery LLC (DBA Central Florida Arbor Care and Mulch Manufacturing Inc.), provides tree services, debris hauling, removal and bio-mass recycling, manufacturing, packaging and sales of next-generation mulch products. The company’s primary corporate objective is to provide a solution for the treatment and handling of tree debris that is historically sent to local landfills and disposal sites, creating an environmental burden and pressure on disposal sites around the nation.

Environmentally Friendly

SGTM and the solutions provided by its Sustainable Green Team are founded in sustainability. The company’s vertically integrated operations begin with the collection of tree debris through its tree services division and collection sites. Tree bio-mass is then moved through the processing division for recycling and manufacturing into a variety of organic, attractive, next-generation mulch products to be packaged and sold to retailers, landscapers, installers and garden centers.

The company’s solutions create a synergistic and environmentally beneficial solution to tree and storm waste disposal that historically has created an environmental burden on landfills and disposal sites around the nation.

SGTM’s customers include governmental, residential and commercial customers and now big box retailers. The company is headquartered in Florida.

Strategic Acquisition

SGTM in February 2020 acquired 35-year-old industry leader and innovator Mulch Manufacturing Inc., an Ohio corporation. Structured as a share exchange, this strategic partnership provides SGTM with a significantly larger footprint in the mulch industry.

The acquisition includes Mulch Manufacturing’s national and international distribution agreements, an increase in production and packaging capacity, and its sales contracts with numerous big box retailers. Mulch Manufacturing includes mulch production, sawmill operation, Natures Reflections colorant manufacturing and equipment manufacturing.

Next-Gen Products

SGTM’s vision and commitment to the environment is paired with Mulch Manufacturing’s revolutionary “next-generation” mulch product, Nature’s Reflection’s Softscape®.

Softscape mulch products, created from natural forest products, are color-enhanced with environmentally safe colorants to provide four-year color retention and are free from contaminants. Safe for people and pets, Softscape allows water and air to penetrate soil and roots, which is vital to plant health and growth.

Expansion Plans

SGTM plans to expand its operations through a combination of organic growth, through its partnership with a nationally recognized waste disposal company, and through strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified.

The company has received final zoning approval for its 100-acre site, located in Lake County, Astatula, Florida, which will serve as its flagship tree debris collection site. The facility will also house the company’s mulch manufacturing, soil composting and production bagging. This prime location includes a 5,000-square-foot building that contains warehouse and office space. The 100-acre property can accommodate millions of cubic yards of organic debris and will allow SGTM’s debris hauling division to realize significant savings on its transportation costs.

SGTM has chosen as its new headquarters the 100,000-square-foot Mulch Manufacturing building in Jacksonville, Florida. The facility comprises centralized operations of Mulch Manufacturing Inc. and National Storm Recovery LLC and has ample room to expand as needed.


SGTM’s leadership team boasts more than 40 years of next-level experience with mulch manufacturing, treating and caring for trees. This team is guided by a roster of highly qualified professionals:

  • Tony Raynor, Chief Executive Officer
  • Edward Lee, Chief Operating Officer
  • Ralph Spencer, Director of Business Development, Strategic Acquisitions
  • Steve Ogden, ISA-Certified Arborist
  • Rick Starcher, Master Chemist
  • Peder K. Davisson, Esq., Corporate/Securities Counsel

Sustainable Green Team Ltd. (OTC: SGTM), closed Thursday’s trading session at $1.25, even for the day, on  volume. The average volume for the last 3 months is 1,114 and the stock's 52-week low/high is $0.200000002/$7.00.

Recent News

Accure Acne Inc.

The QualityStocks Daily Newsletter would like to spotlight Accure Acne Inc..

Accure Acne Inc., based in Boulder, Colorado, is a privately owned medical device company focused on developing an innovative and highly efficient solution to reducing and/or preventing the recurrence of acne vulgaris. “The company’s patented and patent-pending laser technology was designed to help improve acne sufferers’ long-term quality of life by offering a differentiated and impactful solution. . . . The company’s flagship product, the Accure Laser System, was granted CE Mark approval for the treatment of moderate inflammatory acne in 2020, which allows the company to commercialize its product in the European Union while working to develop an exclusive global IP portfolio,” reads a recent article. “The company’s pioneering technology has the potential to disrupt the vast global market of acne therapeutics. It is estimated that there are 40-50 million people affected by acne vulgaris in the United States each year, while roughly 85% of the global population will suffer from acne at some point, according to the company’s April 2021 investor presentation. In 2016, the acne vulgaris market was estimated at $2.6 billion in the U.S. alone.” To view the full article, visit

Accure Acne Inc. is a privately-owned medical device company focused on developing an innovative and highly efficient solution to reducing and/or preventing the recurrence of acne vulgaris. The company’s patented and patent-pending laser technology was designed to help improve acne sufferers’ long-term quality of life by offering a differentiated and impactful solution.

Leveraging the extensive experience of its management and scientific teams, paired with a clear go-to-market strategy and commercialization and regulatory expertise, Accure remains committed to developing a uniquely compelling value proposition.

Accure Acne is headquartered in Boulder, Colorado. The company’s flagship product, the Accure Laser System, was granted CE Mark approval for the treatment of moderate inflammatory acne in 2020, which allows the company to commercialize its product in the European Union while working to develop an exclusive global IP portfolio.

Accure Laser System

The company’s pioneering technology has the potential to disrupt the vast global market of acne therapeutics. It is estimated that there are 40-50 million people affected by acne vulgaris in the United States each year, while roughly 85 percent of the global population will suffer from acne at some point, according to the company’s April 2021 investor presentation. In 2016, the acne vulgaris market was estimated at $2.6 billion in the U.S. alone.

Accure Acne is leveraging several competitive advantages to position itself as a leading company in the acne treatment market. Compared to the main competitors and other acne treatments in the market, the Accure Laser System is designed for efficacy and durable results, in a cost-effective treatment package.

This groundbreaking system is the first commercially developed energy-based device that selectively targets and neutralizes overactive sebaceous glands present in the skin, which are the main source of sebum production and acne vulgaris. By targeting only overactive glands without damaging the surrounding epidermis, the Acne Laser System is likely to yield a durable response, starting with a significant reduction of inflammatory acne lesions, with the goal of eliminating inflammation recurrence in treated areas. The system has been shown to yield a 45%+ reduction in inflammation after just one treatment.

Other key features of the Accure Laser System include:

  • Utilizes a unique wavelength that has not previously been clinically available
  • Leverages unique pulsing strategy, precise and safe closed-loop laser control and integrated temperature monitoring through an infrared camera
  • Is designed for ease of use and relatively short treatment time (30 to 45 minutes)
  • Is equipped with single-use treatment tip and accessories

Treatments are customized to each patient, depending on skin types and case severity, and can range from one to six treatment sessions administered three to six weeks apart.

Accure Acne believes its technology is the only 1,726 nm laser with CE Mark Clearance for acne treatment on the market. The Accure Laser System was developed in partnership with Quanta System, a Milan, Italy, laser tech developer with over four decades of experience.

The company has already launched an early adopter program in the European Union, with the first orders received and delivered in Italy in Q2 2021, through Quanta’s distribution channel. A broader EU commercial launch is scheduled for H2 2021, with plans for an early adopter program in the U.S. to begin in H1 2022 and broader commercial launch in H2 2022.

New Pivotal Acne Study

The Accure Laser System’s efficiency and safety of treatment across all genders, ages, races and skin types has so far been confirmed through four IRB-approved clinical studies. Research showed a 45% reduction of acne lesions after just one treatment and an 80% reduction after the fourth treatment.

Accure Acne is now conducting a new pivotal acne study, restarted in January 2021, based on safety reports from the four IRB-approved clinical trials. This open-label study will enroll 75 patients 16 years and older who will undergo four treatments approximately one month apart.

The study is expected to be completed in early 2022, following several checkpoints to monitor for progress and durability – at three months, six months, nine months and 12 months after the fourth and final treatment. This clinical trial will be key to the company’s efforts to secure FDA approval in the United States.

Private Placement Offering

Accure Acne launched a private placement offering pursuant to Rule 506(c) of Regulation D under the Securities Act. The private placement, launched in April 2021 on the M-Vest platform, aims to raise up to $20 million in Series A Convertible preferred stock.

The proceeds will be used to fund the pivotal acne study, ongoing operations and infrastructure needs, while also creating an EU-based sales team and global marketing teams and conducting pre-commercialization operations in the U.S.

For more information, visit the company’s offering page on M-Vest.

Management Team

Christopher Carlton is Co-Founder, Chief Executive Officer and Chairman of the Board of Accure Acne. He has extensive industry experience as well as a demonstrated track record of entrepreneurial success with high-growth public companies and new product launches on the global medical and aesthetic markets. His previous tenures include CEO of Quanta Aesthetic Lasers USA LLC; President, NA for Syneron-Candela, a prominent company in the aesthetic energy-based device market; Vice President and Global General Manager – Interventional Oncology for Covidien Ltd.; CEO for SRI Surgical; and other leadership positions. In 2016, he was recognized as one of the top 10 CEOs and presidents in the industry by Aesthetics Everything(R). Mr. Carlton is a graduate of the GE Management Development Institute-Crotonville and the Program on Negotiation at Harvard Law School, and he holds a BS in Industrial Engineering (With Honors), a Graduate Diploma in Management and an MBA.

R. Rox Anderson, MD, is the company’s Co-Founder and Chief Scientific & Medical Officer. One of the most influential scientists in the field of energy-based devices in aesthetics and widely considered the father of the aesthetic industry, Dr. Anderson has contributed significant advancements to acne treatment efforts, including pre-clinical, clinical and product development activities built upon his conceptualization and co-development of microscopic target-selective laser therapy. He has been awarded over 60 national and international patents and has co-authored over 437 scientific books and papers cited by other researchers more than 22,800 times. Dr. Anderson is a Harvard Medical School Professor in dermatology, Director of the Wellman Center for Photomedicine, and adjunct Professor of Health Sciences and Technology at Massachusetts Institute of Technology.

Edward Barbera is Co-Founder and Director of Accure Acne. He has more than 35 years of experience developing, running and investing in startups, as well as fundraising, having secured more than $50 million in private equity for a company he founded. Mr. Barbera began his career as a Senior Consultant with Peat, Marwick, Mitchell & Co. and has since held key leadership roles in business development, acquisitions, capital formation and the operation of numerous startups. He has a Bachelor of Business Administration degree with a major in accounting from the University of Massachusetts – Amherst and has previously been a member of the National and Colorado Societies of CPAs.

The Accure Acne leadership and medical teams are further comprised of experts and professionals with extensive experience in technology, software, engineering and medical devices, as well as specialists in acne treatment and laser-based treatment options in dermatology and other medical fields.

Recent News


Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Flora Growth (NASDAQ: FLGC), an all-outdoor cultivator and manufacturer of cannabis-derived products and brands, as signed a Letter of Intent (“LOI”) with Evergreen Pharmacare Pty Ltd. Evergreen is a licensed importer and distributor of medical cannabis products based in Australia, and the LOI calls for Flora to provide raw and finished medical cannabis products for medical cannabis patients. Flora plans to ship the medical-grade cannabis products after the company obtains the correct export licenses and completes its first commercial harvest. The LOI is the second that Flora has signed since recent changes in Colombian law allow the company to sell and export raw cannabis materials, namely dried flower, in addition to derivatives. To view the full press releases, visit

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.


Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Thursday’s trading session at $7, even for the day, on 18,870,659 volume. The average volume for the last 3 months is 1.584M and the stock's 52-week low/high is $2.8499999/$10.2299995.

Recent News

InnerScope Hearing Technologies Inc. (OTC: INND)

The QualityStocks Daily Newsletter would like to spotlight InnerScope Hearing Technologies Inc. (INND).

InnerScope Hearing Technologies (OTC: INND), an emerging and disruptive leader in the direct-to-consumer hearing health technology space, has completed the filing of all required financial reports with OTC Markets and has submitted an attorney opinion letter, and has now been officially declared Pink Current. In order to receive that listing, the company filed all  annual disclosure statements and the financial report for its first quarter ending March 31, 2021, with OTC Markets. According to the announcement, InnerScope is working to meet all requirements to upgrade to and trade on the OTCQB as soon as possible. To view the full press release, visit

InnerScope Hearing Technologies Inc. (OTC: INND) is a Nevada corporation incorporated on June 15, 2012, with its principal place of business in Roseville, California. The company was initially started in 2006 – operating as InnerScope Advertising Agency Inc. – to provide advertising and marketing services to retail establishments in the hearing device industry. On August 25, 2017, the company changed its name to InnerScope Hearing Technologies Inc. to better reflect its current direction as a hearing health technology company that manufactures, develops, distributes and sells numerous innovative hearing health-related products, hearing treatments and hearing solutions, direct-to-consumer (DTC) through a scalable business model.

The company is a manufacturer and a distributor/retailer of DTC, FDA (U.S. Food and Drug Administration) registered, Bluetooth app-controlled hearing aids and personal sound amplifier products (PSAPs), hearing-related treatment therapies, doctor-formulated dietary hearing supplements, proprietary CDB oil for treating tinnitus and assorted hearing and health-related products targeting approximately 70 million Americans suffering from hearing-related problems. The company’s mission is to improve the quality of life of the 70 million people in North America and the 1.5 billion people worldwide who suffer from hearing impairment and/or hearing-related issues.

The management team of InnerScope is applying decades of industry experience and believes it is well-positioned, with its innovative in-store point-of-sale Free Self-Check Hearing Screening Kiosks (“Hearing Kiosks”), to directly benefit when the Over the Counter (OTC) Hearing Aid Act (the “OTC Hearing Aid Law”) is enacted (expected in late 2021 based on the President’s Executive Order issued on July 9, 2021) The OTC Hearing Aid Law allows OTC hearing aids for perceived mild-to-moderate hearing losses to be sold in retail stores without having to see a professional. InnerScope’s Hearing Kiosk is designed to help the tens of millions of Americans with undetected/untreated mild-to-moderate hearing loss treat themselves with the company’s easy, convenient and affordable OTC hearing aids, in-store and/or online.

Industry Game-Changer – New Emerging Market with 48 Million Potential Customers

The following is sourced from The White House Fact Sheet detailing an Executive Order from President Biden aimed at saving Americans with hearing loss thousands of dollars by allowing hearing aids to be sold over the counter at drug stores:

“Hearing Aids: Hearing aids are so expensive that only 14% of the approximately 48 million Americans with hearing loss use them. On average, they cost more than $5,000 per pair, and those costs are often not covered by health insurance. A major driver of the expense is that consumers must get them from a doctor or a specialist, even though experts agree that medical evaluation is not necessary. Rather, this requirement serves only as red tape and a barrier to more companies selling hearing aids. The four largest hearing aid manufacturers now control 84% of the market.”

On July 9, 2021, President Biden noted the following in reference to his Executive Order relating to hearing aids:

“Right now, if you need a hearing aid, you can’t just walk into a pharmacy and pick one up over the counter. You have to get it from a doctor or a specialist. Not only does that make getting hearing aids inconvenient, it makes them considerably more expensive, and it makes it harder for new companies to compete, innovate and sell hearing aids at lower prices.”

“As a result, a pair of hearing aids can cost thousands of dollars. That’s a big reason why just one in seven Americans with hearing loss actually use a hearing aid.”

InnerScope Game-Changers

For InnerScope, this Executive Order could present a significant opportunity. The company is uniquely positioned with a number of strategic advantages and offerings in the space, including:

  • First to Market: Free self-check hearing screening kiosks deployed in national pharmacy chains, big-box retailers & national and local groceries chains
  • Online Hearing Screening Tests: For national retailers to use their websites to attract more customers in conjunction with the company’s in-store hearing kiosks
  • The HearIQ App for iOS and Android users: Offers a free self-check hearing test and provides a user control function for InnerScope’s Bluetooth app-controlled self-adjusting rechargeable hearing devices
  • Customer Monthly Subscription Model: Offering the lowest, most affordable monthly payment options (as low as $42 per month for pair of rechargeable, app-controlled hearing aids) for consumers to purchase hearing aids and receive free upgrades every two years.

The In-Store Hearing Screening Kiosks and Online Free Hearing Screening Tests

Innerscope’s hearing screening kiosk and online hearing screening tests offer free self-check hearing evaluation using the world’s first “Hearing Triage” artificial intelligent pattern recognition software, which has a unique ability to classify both level (degree of loss) and pattern (type of loss). In addition, the software can detect the probable location of the hearing problem and its degree of severity.

The tests are developed as a hearing wellness tool to help track hearing ability and (if tests results indicate a hearing loss) make recommendations for in-store point of sale or online purchase of one of InnerScope’s hearing devices, as well as providing recommendations to see one of the professionals in InnerScope’s local contracted network of hearing health care experts for further follow-up testing if necessary. The software also generates an audiometric report which is instantly emailed to the customer.

The HearIQ App

InnerScope is the creator of the HearIQ App, which offers free self-check hearing tests and provides a user control function for InnerScope’s line of Bluetooth app-controlled self-adjusting rechargeable hearing devices. InnerScope developed the free hearing test part of the HearIQ App to help with the early detection of hearing loss for the 1.5 billion people worldwide who have untreated hearing loss or some form of hearing issues that may be undetected and do not have access to a computer for InnerScope’s online hearing screening test.

Hearing Aid Products

Through its dedicated online store,, InnerScope offers affordable, direct-to-consumer, Bluetooth app-controlled, self-adjusting hearing technology to empower consumers to take control of their hearing care. InnerScope’s hearing technology allows the customer in less than 10 minutes using any smartphone to personalize each hearing device to their hearing needs using an onboard in-ear custom-fit self-testing feature through the HearIQ App.

InnerScope is shifting hearing health care from traditional brick-and-mortar hearing care clinics to customers’ homes by providing a unique solution to give customers top quality, affordable access to hearing aids without the need to see a hearing professional or go to a hearing care clinic. As a result, InnerScope can deliver the same level and quality of hearing technology and expert support for the customer from their homes at a fraction of the cost of traditional channels. All InnerScope hearing aid devices are medical-grade and available with professional remote programming and support services from one of the company’s licensed hearing professionals through the HearIQ App.

Hearing & Tinnitus Dietary Supplements

InnerScope has developed a proprietary line of doctor-designed hearing & tinnitus dietary supplements to help people with hearing problems protect themselves from future hearing issues. There are currently three types of formulas to choose from, including Ear-Ring Relief for the 60 million Americans who suffer from tinnitus, HearingVite + Memory Boost for people with hearing loss and cognitive issues, and HearingVite + Multivitamin for maintaining proper hearing health and levels of nutrients.

Complete Line of Hearing Health Care Products

InnerScope offers a brand label of assorted ear care and hearing aid maintenance products. In support of overall ear health and ensuring maximum performance from its hearing aids and comfort for its customers, InnerScope provides a whole line of care items, including cleaning kits, wipes, spray and drying tablets, ear cleaner for wax removal, a natural lubricant agent for new hearing aids and hydrating lubricating ear gel.

Verified Wholesale and Direct-to-Consumer Sales

InnerScope is a verified wholesaler with Walmart for premium affordable direct-to-consumer hearing aids, personal sound amplification and hearing health accessories. InnerScope also created an easy shopping experience for its hearing and tinnitus vitamins through Walmart and Amazon Prime. With new partnerships in the works, the company aims to add other online and brick-and-mortar establishments to its vitamin distribution network in the future.

Hearing Aid Market Outlook

The global hearing aid market is expected to reach $11.02 billion by 2028, growing at a CAGR of 7.4% during the forecast period. This marks a significant increase from the $6.47 billion value reported in 2020, an increase largely driven by innovations being made in hearing aid technology (

As a leading wholesale provider and direct-to-consumer business, InnerScope is positioned to disrupt the global hearing aid market. Its partnerships with some of the United States’ largest retail distributors and wholesalers are only strengthening the company’s position within the industry.

Management Team

Matthew Moore is the President and CEO of InnerScope Hearing Technologies Inc. He grew up in the hearing health industry, working alongside his grandfather through internships and mentorships. At the age of 10 years old, he became Chief Marketing Officer and Chief Operating Officer of his parent’s private hearing aid practice, the largest in Northern California and the second largest in the state. Matthew has shown his leadership ability by creating distribution partnerships with big industry names and independent retailers/pharmacies.

Kim Moore is the Chief Financial Officer of InnerScope Hearing Technologies Inc. She has worked in the hearing aid industry for over 45 years, helping her father maintain his hearing aid practice in Central Valley, California. She began working on marketing with her father at the age of eight, learning that no customer walks through the door without proper advertising and marketing. As a licensed hearing instrument specialist, Kim has given hearing tests to more than 30,000 people.

Mark Moore is the Chairman and Co-Founder of InnerScope Hearing Technologies Inc. He has over 35 years of experience in hearing aid dispensing, practice management, private label brand management and hearing aid marketing. He has personally fit hearing aids to over 10,000 hearing-impaired people. In addition, he has been responsible for developing and testing proven new industry marketing and advertising methods and best practice strategies, which has made him one of the most sought-after experts in the hearing aid industry. Mark was previously a columnist for Advanced for Audiologists, a global industry publication, and served on the American Academy of Audiology (AAA) advisory board for AudiologyNow conventions. He has also developed patented and patent-pending nutritional supplements for hearing-related issues, aural rehabilitation programs and low-level laser therapy for tinnitus and sensorineural hearing loss.

InnerScope Hearing Technologies Inc. (INND), closed Thursday’s trading session at $0.0138, off by 6.9767%, on 72,955,105 volume. The average volume for the last 3 months is 58.936M and the stock's 52-week low/high is $0.000000999/$0.097999997.

Recent News

Vivos Therapeutics Inc. (NASDAQ: VVOS)

The QualityStocks Daily Newsletter would like to spotlight Vivos Therapeutics Inc. (NASDAQ: VVOS).

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), today announced that it has opened the Vivos Institute training center in Denver, Colorado. The 15,000-square-foot facility was established to provide advanced post-graduate education and training to dentists, dental teams and other health care providers in a live and hands-on setting. The Institute’s emphasis will focus on educating health care providers about OSA, Vivos’ treatments for OSA within their practice areas and providing training on Vivos’ related practice management tools for dentists. To view the full press release, visit

Headquartered in Denver, Colorado, Vivos Therapeutics Inc. (NASDAQ: VVOS) is an emerging global leader in the treatment of mild-to-moderate obstructive sleep apnea (OSA), a debilitating condition affecting nearly 1 billion people worldwide. The company utilizes proprietary, ground-breaking technology, a proven go-to-market strategy, and a powerful executive team dedicated to changing the face of health care by helping people of all ages properly breathe and sleep.

At the core of Vivos’ mission to rid the world of mild-to-moderate OSA is the Vivos System®, a revolutionary clinical breakthrough in the treatment of mild-to-moderate sleep apnea often caused by craniofacial anatomy development. The Vivos System® multidisciplinary treatment protocol involves collaboration between physicians, specially-trained dentists who have completed advanced training in craniofacial sleep medicine, and other ancillary health care providers.

In support of its growth strategy, Vivos has established contract manufacturing facilities in the U.S., Canada and Asia.

Market & Technology Overview

Craniofacial developmental deficiencies, such as underdeveloped upper and lower jaws, are among the leading causes of OSA. According to a 2019 analysis from researchers at the University of California, San Diego, an estimated 81 million adults in North and South America suffer from moderate to severe OSA. The United States has the highest amount of these patients, with approximately 54 million adults affected, according to the report.

Registered with the FDA as a Specification Developer, Vivos develops and markets a number of oral appliances. Its technology represents the first non-surgical, non-invasive and cost-effective treatment for the estimated hundreds of millions of people globally who suffer from mild-to-moderate OSA.

Vivos integrates its specially designed, customized appliances into a patient-specific, multi-disciplinary clinical protocol, giving trained dental and medical providers the tools and roadmap needed to address certain craniofacial conditions that studies have shown to be associated with sleep-disordered breathing—including mild-to-moderate OSA.

The system’s treatment protocol involves collaboration between physicians, specially trained dentists who have received advanced training in craniofacial sleep medicine, and additional health care providers. Vivos-trained clinicians can be found in almost every major city in the U.S. and in many countries throughout the world. The company’s oral appliances have shown to be effective in over 15,000 patients successfully treated worldwide by approximately 1,200 trained dentists.

A New Paradigm in Sleep Medicine

Vivos’ proprietary system poses the potential to be the biggest breakthrough in the treatment of mild-to-moderate OSA since CPAP.

The Vivos System has been specifically designed to promote the proper growth and development of the hard and soft tissues surrounding and comprising the oral cavity, nasal cavity, upper and lower jaws, and other tissues which together form and shape the upper airway. As these areas develop more fully using the Vivos System, a patient’s airway typically widens and expands, enabling them to breathe properly through their nose. With a more open and less obstructed airway, and easier nocturnal breathing, the symptoms of SDB tend to diminish over time, and patients often report they no longer suffer from the adverse effects of SDB or OSA.

Use of the Vivos System is variable and case dependent, but typically recommended to be worn daily for 12 to 16 hours starting in the early evening and continuing overnight. The total treatment time typically ranges from 12 to 24 months, with 18 months being the approximate mean treatment time.

Biomimetic Oral Appliance

Vivos Therapeutics believes that the Vivos System technology represents the first non-surgical, non-invasive and cost-effective treatment for people with mild-to-moderate OSA.

Combining technologies and protocols that can alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can significantly reduce symptoms and conditions associated with mild-to-moderate OSA.

The Vivos System treatment is typically less than $10,000 and is often reimbursable by medical insurance as an out-of-network benefit.

A potentially serious medical problem with an alternative treatment therapy available in the dental office.

Hard and soft tissues of the craniofacial complex can be non-surgically enhanced using the proprietary Vivos® System devices and clinical protocols.


R. Kirk Huntsman – CEO, Director
With experience in strategic development, technology acquisition and product planning, key talent recruitment, and target market prioritization, Huntsman brings a broad vision paired with leadership and strategic planning skills. He has significant start-up experience in a diverse range of market sectors, including medical devices, dental management, dental practice valuations and transitions, multi-location retail, financial and capital formation, consulting, outsourced services, imports and exports (China), medical services, and software and technology.

Dr. Dave Singh – Founder, Director
A doctor three times over in dental medicine, craniofacial development, and orthodontics, Dr. Singh was educated primarily in England and has lectured in North America, Europe, Asia, and Africa. The Global Summits Institute recently named Dr. Singh as one of the Top 100 Doctors in Dentistry.

Vivos Therapeutics Inc. (NASDAQ: VVOS), closed Thursday’s trading session at $3.12, off by 0.319489%, on 199,281 volume. The average volume for the last 3 months is 299,827 and the stock's 52-week low/high is $3.00/$14.4099998.

Recent News

AmpliTech Group Inc. (NASDAQ: AMPG)

The QualityStocks Daily Newsletter would like to spotlight AmpliTech Group Inc. (NASDAQ: AMPG) (NASDAQ: AMPGW).

AmpliTech Group (NASDAQ: AMPG), a designer, developer and manufacturer of state-of-the-art components and semiconductor chips for satellite and 5G communications networks, defense, space, and other commercial applications, was featured in the latest episode of The Stock2Me Podcast, an InvestorBrandNetwork (“IBN”) solution to provide specialized content distribution via widespread syndication channels. AMPG’s Director of Communications Shan Sawant joined the latest episode to discuss AmpliTech’s business model and offer an overview of the company’s proven, decades-long track record of providing vital radio frequency components to an impressive list of clients. “AmpliTech provides high-quality radio frequency (‘RF’) components that allow for high performance, low noise wireless connections in devices and systems,” Sawant said. “As we know, today, virtually every mobile device requires a wireless signal of some kind, and systems are beginning to need to process more data than ever before. That creates an unprecedented demand for signal bandwidth to move applications and data in a fast and highly reliable way.” To view the full press releases, visit and

AmpliTech Group Inc. (NASDAQ: AMPG) (NASDAQ: AMPGW) designs, develops and manufactures custom radio frequency (RF) components for the commercial, SATCOM, space and military markets. In addition to developing new products for the 5G/6G wireless ecosystem and infrastructure, the company has placed focus on the development of leading-edge solutions in quantum computing in support of U.S. efforts to reach the coveted position of quantum supremacy. The company maintains a commitment to R&D that allows it to remain at the forefront of emerging technologies. AmpliTech aims to use its advanced techniques and IP to provide tomorrow’s technology today, improving everyone’s quality of life.

AmpliTech was founded by Fawad Maqbool in 2002 to fill the need for affordable, high-quality, customized and state-of-the-art amplifiers and components. Headquartered in Bohemia, New York, the company currently has distributors and representatives available worldwide.

Product Portfolio

AmpliTech’s mission is to develop quality, state-of-the-art microwave amplifiers by leveraging its experience, proven technical expertise and superior design heritage. The company’s products cover a frequency range from 50 kHz to 44 GHz, with plans to eventually offer designs up to 100 GHz. Its current catalog includes:


Passive Components

All the company’s products come with a satisfaction guarantee, as the company is fully committed to providing only high-quality products free from manufacturing and material defects and guaranteed to perform according to applicable specifications.

Consulting Services

Leveraging more than 100 years of combined experience in microwave systems and component design ranging from active components to passive devices, AmpliTech also provides valuable consulting services and technical assistance to its customers.

With capabilities ranging from initial design to final manufacturing and delivery, the company’s team also offers project management services and advice on both technical aspects and how to handle business issues such as resource allocation, customer contact, budget restraints, time limits and more.

Other key benefits of AmpliTech consulting services that can give its customers a definitive edge include:

  • Timely technical assistance
  • Little or no learning curve
  • Less long-term costs associated with full-time employees with benefits and salaries
  • Availability when necessary
  • Customer support with schedules, project management and on the job training
  • Access to technology
  • Partnering for manufacturing and/or complete turn-key product solution
  • Personal guidance from concept to development
  • Custom designs for each application

Market Outlook

The global microwave devices market was valued at $7.44 billion in 2019 and is expected to grow at a CAGR of 3.23% and reach $9 billion by 2025 ( Governmental expenditures in the defense and space communications sectors are expected to expand the opportunities for growth within the industry.

AmpliTech continues to follow its strategy of identifying key elements in today’s technological revolution. It is leveraging its technical expertise and experience to align product portfolios and IP with innovation ( The company has plans to be a catalyst in the enhancement, development and distribution of breakthroughs in the following sizeable markets:

  • High Speed Terrestrial and Satellite Terminals (SATCOM, “Internet in the Sky”)
  • 5G/Wi-Fi6E and 6G wireless infrastructure (Cellular Base Stations, Small Cells, Private Wi-Fi Networks)
  • IoT (Internet of Things)
  • Cloud Farms, Big Data and MEC architecture
  • Quantum Supercomputers/Quantum Research
  • Deep Space Astronomy
  • Autonomous Self-Driving Vehicles
  • Telemedicine, AR/VR (Augmented and Virtual Reality)
  • Drones, UAVs (Unmanned Aerial Vehicles)
  • Cyber-security
  • Military/Defense ECM/EW

Management Team

Fawad Maqbool is the Founder, President, CEO and CTO of AmpliTech Group Inc. He has been in the microwave industry for over 30 years. Mr. Maqbool spent 14 years developing state-of-the-art amplifiers and components for MITEQ Inc., a leading microwave and communications equipment supplier. He founded AmpliComm in 2000, which was subsequently acquired by Aeroflex Inc. Mr. Maqbool has management and design experience, which has led to the development of microwave technology on a commercial and military level. He holds a B.S.E.E in Microwave Engineering and a B.S.E.E in Bio-Medical Engineering from CUNY and an M.S.E.E from the Polytechnic University of New York.

Louisa Sanfratello is the company’s CFO. She is a Certified Public Accountant (CPA) and has worked in various industries since 1998. During this time, she held roles as an accountant for charities and schools, consisting of the preparation of official financial documents and day-to-day financial management requirements. Ms. Sanfratello began her professional career in 1987 at Holtz, Rubinstein & Co., a public accounting firm. She gathered two years of experience there before gaining her CPA and taking on more challenging roles.

Brandon Worster is the company’s Director of Engineering. He joined AmpliTech at the end of 2019, bringing over 14 years of design and management experience. His specialty is Low Noise and Medium Power Amplifiers, but Mr. Worster also has vast experience with various systems, including RF/Microwave devices and systems. He holds a master’s degree in electrical engineering and is an adjunct professor at Farmingdale University in New York.

John P. Pastore is AmpliTech’s Director of Sales. He has worked in the microwave industry for more than 35 years, including time with some of the industry’s leading names. Mr. Pastore is a hands-on professional who has experience that spans over 20 years with progressive roles that blend technical, manufacturing, customer service and management expertise. He is an extremely valuable asset to the company as it moves forward due to his business savvy approach and deep industry knowledge. He has a B.S. in Business Management.

M. Syed handles Technical Sales and is the company’s Director of IT. He is an electrical engineer with more than 10 years of business experience. Since 2011, he has led Technical Sales for AmpliTech, and he recently became the President and CEO of his own company while also serving as Chief Technical Sales consultant for numerous other companies and groups in New York City. Mr. Syed has been in the IT industry for 25 years. He is a Computer Engineer by trade and a Certified Netware Engineer and Microsoft Certified Systems Engineer.

AmpliTech Group Inc. (AMPG), closed Thursday’s trading session at $4.22, off by 0.938967%, on 129,816 volume. The average volume for the last 3 months is 316,893 and the stock's 52-week low/high is $0.879999995/$19.7999992.

Recent News

Green Hygienics Holdings Inc. (OTCQB: GRYN)

The QualityStocks Daily Newsletter would like to spotlight Green Hygienics Holdings Inc. (OTCQB: GRYN).

  • The company plans to incorporate systemic environmental, social, and governance (“ESG”) factors into business planning and investment decision-making
  • The initial Sustainability Accounting Standards Board (“SASB”) report has been completed, and sustainability consulting firm KERMIDA Inc. is currently organizing the data compiled by Green Hygienics
  • An ESG program can significantly benefit companies in the industry, from drawing in more investors to winning new business, gaining better talent and improving media coverage
  • The industrial hemp market size is expected to reach $15.26 billion by 2027 due to the rising demand for food, supplements, cosmetics, and personal care items

Green Hygienics Holdings (OTCQB: GRYN), a California-based innovative and tech-based enterprise that is focused on the high cultivation standards, processing, and manufacturing of industrial hemp for pharmaceutical-grade bioactive cannabinoids, is enhancing its corporate responsibility and sustainability goals to empower environmental progress. The company plans to incorporate systemic environmental, social, and governance (“ESG”) factors into business planning and investment decision-making.

Green Hygienics Holdings Inc. (OTCQB: GRYN) is a California-based innovative technology-driven enterprise focused on the high standard cultivation and processing of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids.

The company aims to be a leader in compliance and capabilities in the hemp and cannabinoid supply marketplace. By leveraging state of the art technologies, the company intends to open up a whole new world of novel cannabinoids and targeted bio-delivery technologies never before explored, solving the issues of stability, pharmacokinetics, biological tissue penetration and bioavailability.

Dedicated to creating the hemp industry’s safest and finest quality products, the company will be uniquely positioned to deliver product efficacy and supply chain solutions to consumers, as well as to leverage these within its own products and brand portfolio.

USDA Organic Certification and FDA Registration

On August 26, 2020, Green Hygienics registered with the U.S. Food and Drug Administration pursuant to the Federal Food Drug and Cosmetic Act, as amended by the Bioterrorism Act of 2002. This registration strengthens the company’s core mission to provide product efficacy to the pharmaceutical industry and consumers alike.

On September 30, 2020, Green Hygienics was granted USDA Organic Certification (7 CFR Part 205) for the cultivation and post-harvest processing of industrial hemp by the California Certified Organic Farmers for its Sol Valley Ranch property. This certification further enables the company to supply certified organic hemp products to national and international markets.

Market Opportunity

Green Hygienics is focused on finding, acquiring and developing strategically positioned businesses, as well as the best innovations within the hemp industry – a fast-progressing market with remarkable opportunities for growth. The industrial hemp market is expected to reach $5.33 billion in 2020 and is projected to rise to $15.26 billion by 2027, achieving a CAGR of 15.8%, per Grand View Research.

Capital Structure

GRYN has less than 42 million shares outstanding, fully diluted. The company has just 7.2 million common shares in float and boasts a balance sheet with no toxic debt or overhang.

Key Management

Dr. Levan Darjania serves as the company’s Chief Science Officer. Darjania has over 26 years of experience in biotechnology and pharmaceutical drug development. His research and development experience has led him to develop many in-house and collaborative R&D programs over the course of his career.

Kyle MacKinnon serves as GRYN’s Chief Operating Officer. He has extensive knowledge in cannabis processing and was previously the Business Development Manager of Advanced Extraction Systems Inc., a leader in CO2 Supercritical Fluid Extraction. MacKinnon brings over 20 years of sales and management experience to the company.

Ronald Loudoun is the President, CEO, Secretary and Director of Green Hygienics. He received an undergraduate business degree from the British Columbia Institute of Technology. Before joining Green Hygienics, he was the founder and a director of renewable energy firm Archer CleanTech Inc.

Jerry Halamuda is the Senior Vice President of Business Development of the company’s Agriculture Division. He has an extensive career working in the agriculture and horticulture industry. Halamuda has founded, managed and operated multiple successful companies, including Color Spot Nurseries.

John Gildea is GRYN’s Senior Vice President of Corporate Development. He has over 20 years of experience working within the private and public markets. His expertise includes negotiating and structuring private and public financing and mergers. During the course of his work, Gildea has established trusted relationships with a network of equity and capital partners.


Green Hygienics Holdings Inc. (OTCQB: GRYN), closed Thursday’s trading session at $1.88, off by 1.0526%, on 30,394 volume. The average volume for the last 3 months is 70,200 and the stock's 52-week low/high is $0.457549989/$2.45000004.

Recent News

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)

The QualityStocks Daily Newsletter would like to spotlight Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF).

  • Approximatively 75-85% of patients with confirmed cases of bladder cancer are diagnosed with non-muscle invasive (“NMIBC”)
  • Imagin Medical’s innovative technology is targeting this type of bladder cancer and set to be completed in 2022 
  • Blue light cystoscopy helps surgeons visualize the cancerous cells that are not detected by white light, enabling an improved resection

To address these issues,  Imagin Medical (CSE: IME) (OTCQB: IMEXF) has developed the i/Blue Imaging System(TM), an innovative technology designed to significantly improve the way surgeons visualize cancerous cells for more accurate bladder resection. This patented technology allows for white and blue light images to be projected side-by-side simultaneously, enabling better surgical technique. The i/Blue System will attach to most endoscopes currently on the market, protecting hospitals’ investment in instruments they already own and enabling their adoption of blue light cystoscopy at a significant cost savings.  

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures. Its initial focus is on bladder cancer.

The company’s first product is the i/Blue Imaging™ System, based on advanced optics and light sensors and employing patented ultrasensitive imaging technology. Imagin Medical believes the system can significantly improve surgeons’ ability to visualize and remove cancer cells.

Founded in 2016 and headquartered in Boston, Massachusetts, the company works to enhance its market potential by expanding its technology to multiple endoscopic indications, such as laparoscopic, colorectal and thoracic procedures, accommodating multiple contrast agents and illumination sources.

i/Blue Imaging™ System

The conventional method used for visualizing bladder cancer during surgery is an endoscopic procedure called a cystoscopy. This procedure uses white light to illuminate the bladder. White light has been used for decades and is the standard for more than 90% of the market. Blue light cystoscopy uses blue-filtered white light, which addresses the limitations of white light (such as detecting flat tumors and the fine edges that may result in cancerous cells being left behind during removal).

Blue light uses a contrast agent that causes cancer cells to fluoresce when illuminated. Surgeons are then able to more effectively visualize and resect the margins of bladder tumors to reduce the risk of recurrence. Notably, the use of the white light is still necessary during a blue-light procedure so that the surgeon can orient their position within the bladder.

Imagin Medical’s i/Blue Imaging System addresses the limitations of both white and blue light cystoscopies. The i/Blue System combines the white and blue light with an FDA-approved imaging agent and simultaneously displays side-by-side images in real-time, without the necessity to switch back and forth between the two images.

The i/Blue Imaging System is unlike other methods available on the market today. It is external to the body and can attach to almost any endoscope model currently in use. This way, hospitals adopting Imagin Medical’s technology have the ability to use their current endoscopes without the need to purchase new equipment.

Bladder Cancer Prevalence

The company’s initial focus is bladder cancer, which is the sixth most prevalent form of cancer in the United States. In 2020, the number of new bladder cancer cases is expected to total 81,400, accounting for 4.5 percent of all new cancers diagnosed. The death rate in 2020 for cancer deaths associated with the bladder is forecast at 17,980, or 3% of all cancer-related deaths (

Bladder cancer also has one of the highest recurrence rates among all forms of cancer, leaving about 600,000 people in fear that their cancer will return, according to Imagin Medical. The company is committed to addressing this issue, and i/Blue demonstrations have indicated that the use of both white and blue light can enhance accuracy of detection and removal of cancer cells, potentially lowering recurrence rates.

Based on Verified Market Research, the global bladder cancer research market was valued at $3.43 billion in 2018. It is estimated to grow with a CAGR of 4.03% through 2026, resulting in a projected $4.71 billion market (

Management Team

E. James Hutchens is the Chief Executive Officer of Imagin Medical Inc. He is a proven entrepreneur with over 30 years of experience in management in the medical technology industry. Hutchens served as a managing partner with Origin Partners, a $55 million early-stage venture capital fund. He was also the founder and CEO of both Microsurge Inc. (a venture-backed minimally invasive surgical company) and Choice Therapeutics (an advanced wound-care company). He is a former member of the Board of Directors of the Brigham and Women’s and Faulkner hospitals. Hutchins holds a BS in Business Administration from Boston University.

John Vacha is the company’s Chief Financial Officer. He has 20 years of experience in the health care industry. Prior to Medtronic’s acquisition of Intact Medical Corp. in 2017, Vacha was the company’s President, CEO and a board member for seven years. He is a licensed CPA in Massachusetts. Vacha has an MBA and an MS in Accounting from Northeastern University in Boston. He is also a serving member of the Board of Directors at the South Boston Health Center. He currently has two patents in electrosurgical instrumentation.

Michael G. Vergano is the Director of Operations of Imagin Medical. He has been the President of The Harvest Group Inc. since 1998, where he has provided consultant services for startups and major corporations. Vergano has over 30 years of experience in the medical device industry. He has held management positions at Microsurge Inc., Ciba Corning Diagnostics and Boston Scientific Corp. He is currently the holder of 11 medical device patents and holds a BS in Mechanical Engineering from Tufts University.

Pam Papineau is the company’s Director of Regulatory Affairs. She has over 30 years of experience in quality and regulatory affairs with Boston Scientific, Baxter and Cogentix. She has served as a consultant on various devices including imaging, endoscopy, orthopedic, GI/GU and cardiovascular applications. Papineau has successfully prepared dozens of FDA pre-market and EU submissions to support CE marking of a broad spectrum of medical devices. She is an ASQ Certified Quality Engineer, a Certified Biomedical Auditor, a Certified Quality Auditor and an ISO 13485:2016 Lead Auditor, and she is certified by the Regulatory Affairs Professional Society – U.S., EU and Canada. Papineau works with the company’s legal counsel to prepare pre-submission meetings with the FDA and activities through the regulatory approval process.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF), closed Thursday’s trading session at $0.3939, off by 1.844%, on 3,800 volume. The average volume for the last 3 months is 5,748 and the stock's 52-week low/high is $0.200000002/$1.16999995.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Wednesday's trading